Slideshow

9 Facts About Step Therapy

Step therapy policies may be blocking timely access to care for rheumatology patients, finds a new report by Xcenda, an AmerisourceBergen company. The report finds that patients are more likely to be nonadherent or pay out of their own pocket for drugs. Learn more in this slideshow. 

Step therapy policies may be blocking timely access to care for rheumatology patients, finds a new report by Xcenda, an AmerisourceBergen company. The report finds that patients are more likely to be nonadherent or pay out of their own pocket for drugs. Plus, if the treatment doesn't work, 40% patients stop taking them rather than try to get approval for a new treatment. 29% stopped taking drugs due to out-of-pocket costs and 27% stopped taking drugs because the healthcare insurance didn't cover the drug. Learn more in this slideshow.RELATED:  "Report Shows Drug Costs Take Precedence Over Patients' Well-Being"REFERENCE:  Jennifer Snow, MPH; Madelaine A. Feldman, MD, FACR; Jenna Kappel, MPH, MA. "The Impact of Step-Therapy Policies on Patients." December 2019. A white paper published by Xcenda, an AmerisourceBergen company.

Related Videos
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
© 2024 MJH Life Sciences

All rights reserved.